A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

• Status: Not yet recruiting
• Trial end date: 2027-10-01

Summary

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

• Phase: Phase 3

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Prednisolone; Prednisone